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Autogenous bone is still considered the “gold standard” of regenerative and reconstructive procedures involving mandibular de-
fects.However,harvestingofthismaterialcanleadtomanycomplicationslikeincreasingmorbidity,expandingofthesurgicaltime,
and incomplete healing of the donor site. In the last few years many authors looked for the development of eﬀective reconstruction
procedures using osteoinductive factors without the need for conventional bone grafting. The ﬁrst-in-human study involving the
useofBoneMorphongenicProteins(rhBMP)formandibularreconstructionwasperformedin2001byMoghadam.Onlyfewarti-
cles have been reported in the literature since then. The purpose of this study was to search and analyze the literature involving the
use of rhBMP for reconstruction of mandibular defects. In all the studies reported, authors agree that the use of grown factors may
represent the future of regenerative procedures with more research necessary for conﬁrmation.
1.Introduction
Tissue engineering holds great promise for revolutionizing
many grafting procedures. Continuity defects of the mandi-
ble frequently result from tumor removal or signiﬁcant trau-
ma, and reconstruction of these defects can be challenging.
Fordefectswithextensivehardandsofttissueloss,microvas-
cular free tissue transfer often provides an excellent recon-
structive option. However, signiﬁcant site morbidity as well
as non ideal bone stock for dental implant rehabilitation may
occur [1].
The development of bone morphogenic proteins (BMPs)
has oﬀered an alternative to traditional bone grafting, which
has been the gold standard for oral and maxillofacial recon-
struction [2]. Clinical application of BMPs has evolved to
include defects of the facial skeleton including those involv-
ing the mandible and maxilla [3] .T h e r eh a v eb e e nm a n yr e -
ports of the use of BMPs regarding orthopaedic as well as
alveolar augmentation. There have been few studies address-
ing the use of BMP in reconstructing critical-size defects of
the mandible.
Thepurposeofthisstudyistoevaluatethediﬀerentstudy
present in the literature concerning the use of growth factors
for the reconstruction of mandibular defects, comparing the
method and the ﬁnals results. A well-identiﬁed guideline is
infactnotstillavailableand,becauseofthat,signiﬁcativedif-
ferences could be ﬁnd analysing the literature on that topic.
2.Background
Failure to adequately restore mandibular continuity defects
often result in poor function for the patient postsurgically.
Various bone grafting and bone manipulation techniques
are available for restoring large mandibular bony defects. An
ideal osseous grafting treatment should involve use of a bone
inductive material that would be reliable, biocompatible,
long-lasting, and capable of restoring mandibular continuity
with minimal morbidity. Particulate marrow and cancellous2 Plastic Surgery International
autogenous bone meet these requirements, but must be har-
vested from a donor site that often results in insuﬃcient
bone graft material, at an added cost, and patient harvest-
graft-site morbidity [4–6]. The development of eﬀective re-
construction procedures using osteoinductive factors, such
as growth factors (GFs), without the need for conventional
bone grafting has allowed the possibility to decrease surgical
morbidity [7–9].
Three vital components necessary for the engineering of
bone are bone-forming cells, osteoinductive growth factors,
and an osteoconductive scaﬀold. The osteoconductive scaf-
fold provides immediate mechanical support, mimics the
bony extracellular matrix, and guides the formation of bone
in the desired shape and place. The main role of the growth
hormoneistorecruitmesenchymalstemcellstotheareaand
inﬂuence them to diﬀerentiate into an osteogenic cell lineage
[10]. Autogenous bone is considered the gold standard for
the reconstruction of the mandibular bone because it owns
all these properties. Unfortunately, the risk of morbidity is a
concern [11, 12] and has led to the great appeal of protein
guided bone regeneration.
Many growth factors are involved in osteogenesis [2, 13].
Bone morphogenetic proteins (BMP-2 and BMP-7), trans-
forminggrowthfactorbeta(TGF-β),insulin-likegrowthfac-
tors I and II (IGF I and II), platelet-derived growth factor
(PDGF), ﬁbroblast growth factors (FGFs), and vascular en-
dothelial growth factor (VEGF) have been proposed for use
inbonetissueengineering. Bonemorphogenetic proteinsare
a group of proteins known to play a role in osteogenesis and
chondrogenesis. BMP-2 and BMP-7 are known for their
osteoinductive qualities [10, 14]. Recombinant human BMP
in combination with a collagen sponge carrier made out of
type 1 bovine collagen has been approved by the Food and
Drug Administration and is used for speciﬁc clinical situa-
tions, that is, interbody spinal fusion, open tibial fractures,
sinus augmentation, and localized alveolar ridge augmenta-
tion after dental extraction.
3.MaterialsandMethods
3.1. Literature Review. An electronic search was conducted
on MEDLINE, EMBASE, and CENTRAL database through
PubMed, Embase, and Cochrane. The search was based on
two aspects: reconstruction of mandibular defects regardless
of aetiology and the use of rhBMP, both to be found in
titleand/orabstract.Forthesearchofmandibularreconstru-
ction, synonyms were taken into account. The search results
werecheckedfordoubles,thentheuniquesearchresultswere
checked against our exclusion criteria. Due to the small
amount of results, the authors were obligated to take in con-
sideration also studies in which the number of the patient
was minimum, including case reports. There are no com-
parative studies, in which the use of rhBMP is compared
with autogenous bone for mandibular continuity defects.
The only exclusion criteria used were as follows: study
performed in nonhuman models and/or language of the
full article other than English. The search yielded 8 results
(Table 1).
3.2. Full Text Analysis. The articles were evaluated with re-
g a r dt ot y p eo fs t u d ya sw e l la sn u m b e ro fp a t i e n t st r e a t e d .
The type of BMP used, the size of the defect, the type of car-
rier, and any graft extender used were determined from the
reports. The method of measuring the regenerated bone as
well as aetiology of the defect was analyzed. Length of fol-
lowup, whether dental implants were used to rehabilitate the
patient, and complications (no bone formation) were also
recorded.
Four of the eight articles considered were published by
the same author [1, 3, 4, 15]. In between the other four arti-
cles, the ﬁrst one in terms of date of publishing is by Mogha-
dam et al. [16], followed by Clokie and S´ andor [17], Carter
et al. [18], and Glied and Kraut [19]. Of the 8 articles taken
in consideration 7 used rhBMP 2 for the reconstruction of
the mandible with only Clokie and S´ andor using rhBMP 7.
One other article, proposed by P. Warnke et al. [20]a n d
P. H. Warnke et al. [21] in 2004, describes the mandibular
reconstruction using 7mg of rhBMP 7 and a prefabrication
technique. This article has not been considered in our paper
because the healing process was not obtained in situ but into
the latissimus dorsi muscle and the new reconstructed man-
dible was then transplanted as a free bone-muscle ﬂap to
repair the mandibular defect. This case represents the only
case in the literature in which the transplanted technique is
usedformandibularreconstructionandforthatreasonisnot
comparable with the other studies considered in our paper.
4. Results
BMPs were used in combination of an absorbable collagen
carrier (ACS) in seven of the eight cases. The only case per-
formed in a diﬀerent way was done by Clokie and S´ andor.
They used rhBMP 7 in addition to demineralised bone mat-
rix (DBM). In all the other cases the carrier used was an ab-
sorbable collagen sponge (ACS), except for the ﬁrst case re-
ported in the literature, in which Moghadam et al. used a
poloxamer-based gel to create the bioimplant. Carter et al.
and Clokie and S´ andor used demineralised bone matrix, as
well as Herford [1], in addition to rhBMP 2 and ACS. The
dose used varied considerably in between the ﬁrst case, re-
ported by Moghadam and the following ones. Moghadam’s
d o s eu s e dw a si nf a c t2 0 0 m g[ 16], while the quantity of
BMP reported in the other studies varies in between 4.2mg
[15]a n d2 4m g[ 19], so considerably inferior to the ﬁrst one
reported in the literature. The authors’ opinion is that the
ﬁrst dose used was excessive but justiﬁed by the absence of
previous studies. The high cost of rhBMP obligated a signif-
icant reduction of the bioimplant’s amount used in the most
recentstudiesbutitdidnotseemtoinﬂuencethereconstruc-
tion results.
The most common etiology for the defect was benign
neoplasms, with diagnosis of ameloblastoma, juvenile ossi-
fying ﬁbroma, giant cell tumor, or traumatic. In his study
Carterdescribedonecaseofmandiblereconstructionfollow-
ing enucleation of an odontogenic keratocyst. The fact that
all the cases reported in the literature involved benign neo-
plasm and not malignant lesions conﬁrms the contra-
indication in using rhBMP in these kind of pathologies, asPlastic Surgery International 3
Table 1: Selected articles present in the literature.
Authors Title Journals Years
Moghadam et al. [16] Successful mandibular reconstruction using a BMP
bioimplant The Journal of Craniofacial Surgery 2001
Herford et al. [3] Clinical applications of rhBMP-2 in maxillofacial
surgery
Journal of the California Dental
Association 2007
Clokie and S´ andor [17] Reconstruction of 10 major mandibular defects using
bioimplants containing BMP-7
Journal of the Canadian Dental
Association 2008
Herford and Boyne [4] Reconstruction of mandibular continuity defects with
bone morphogenetic Protein-2 (rhBMP-2) Journal and Maxillofacial Surgery 2008
Carter et al. [18]
Oﬀ-label use of recombinant human bone
morphogenetic protein-2 (rhBMP-2) for
reconstruction of mandibular bone defects in humans
Journal and Maxillofacial Surgery 2008
Herford [1] rhBMP-2 as an option for reconstructing mandibular
continuity defects Journal and Maxillofacial Surgery 2009
Glied and Kraut [19] Oﬀ-label use of rhBMP-2 for reconstruction of
critical-sized mandibular defects New York State Dental Journal 2010
Herford and Cicci` u[ 15]
Recombinant human bone morphogenetic protein type
2 jaw reconstruction in patients aﬀected by giant cell
tumor
The Journal of Craniofacial Surgery 2010
suggested by FDA. The size of the reconstructed defect, when
reported, varied from 3 to 9cm. The measurement system to
evaluate the size of the defect and the following bone regen-
eration was in all the cases computed tomography (CT) scan
prior to, immediately after surgery and at the ﬁnal followup.
In his study Moghadam also used an incisional biopsy to
evaluate the amount of bone regeneration and remodelling.
The follow-up period in these studies varied from 2 to 22
months, as reported in Table 2.
To evaluate the ﬁnal result, all the authors based their
analysis on the quantity of regenerated bone in the grafted
area. The possibility to perform a prosthetic rehabilitation
was considered the key for success in most of the studies. Im-
plant rehabilitation was shown in two of the studies consid-
ered. Clokie and S´ andor described it in four of his ten pa-
tients and Herford, in his work of 2009, in one of two
patients. The other studies did not describe any implant re-
habilitation but in six of the eight articles CT scans showed
adequate height and width to support dental implants. Glied
and Kraut described a complete failure of the bioimplant
in all of his three patients and the necessity of a following
reconstruction using autogenous bone grafts. In two of their
ﬁve patients furthermore Carter et al. had to resort to a
second surgery with autogenous bone graft due to the failure
of the rhBMP 2. A total of 37 patients were treated in the
reviewed studies: 32 were successful (86.5%), whereas 13.5%
failed to form adequate bone with rhBMP-2.
5.CaseExample
A 20-year-old patient presented for evaluation of his mandi-
bular tumor (Figure 1). He had a biopsy performed which
revealed an aggressive benign lesion identiﬁed an ameloblas-
toma involving the left mandible. The tumor was resected,
and a reconstruction plate was placed. A combination of
rhBMP-2 (Infuse Bone Graft—Medironic, TN) and demine-
ralised bone matrix (DBX—Synthes, Paoli, PA) was used to
reconstruct the defect. A titanium mesh was placed on the
superior aspect of the defect to aid in preventing soft tissue
collapse during bone formation (“space maintenance”). The
patient was rehabilitated with 4 dental implants after 8
months of healing.
6. Discussion
The ﬁrst reported mandibular reconstruction using rhBMP
in a human was reported by Moghadam et al. in 2001 [16].
Over the ten years since the ﬁrst publication, only a few ar-
ticles have been reported. The lack of studies does not allow
a systematic review with a high level of evidence. The present
study in fact, because of the small number of articles avail-
able, includes case reports and case reviews. The higher level
of evidence in the studies reviewed is obtained by Herford
and Boyne [4], who described the treatment of 14 patients
with a followup of six months. Clokie and S´ andor [17]d e s -
cribed 10 cases with a followup of 12 months, Carter et al.
[18] 5 cases and 22 months of followup, and Glied and Kraut
[19] showed the treatment of 3 patients in 12 months. In his
other 3 works Herford [1, 3, 15] described two patients in
onearticleandoneintheothertwowithanaveragefollowup
of 4 months. Moghadam et al. [16] described one case in his
work,with afollowup of9 months. Thetotal of patients pre-
sent in the literature, treated with rhBMP for mandibular
reconstruction since 2001, is 37. This is a small number if
compared with the data present concerning alveolar cleft re-
construction using rhBMP, for which more than 50 studies
are reported in the literature [10].
rhBMP-2 was used in all case series with the exception
of Clokie and S´ andor, who used rhBMP 7. In 6 over 7 cases
the carrier is an absorbable collagen sponge (ACS). In his
study Moghadam used a poloxamer-based gel in addition
to rhBMP2, to create the bioimplant. Only three studies4 Plastic Surgery International
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Figure 1: (a) Panoramic radiograph exam shows the presence of a radiolucent lesion in the left mandibular body. The diagnosis was
ameloblastoma. (b) CT scan images of the lesion. (c) Tumor specimen, approximately 6cm. (d) Reconstruction plate in place to reconstruct
the mandible. (e) Bioimplant (rhBMP-2/ACS and demineralised bone allograft) inserted and covered by titanium mesh. (f) Postoperatory
CT scan. (g) Panoramic radiograph showing implant rehabilitation after 8 months.6 Plastic Surgery International
[17,18]utilizeddemineralisedbonematrix,andinonestudy
autogenous bone as a graft extender was used. The addition
of a graft extender is recommended in order to promote
quicker calciﬁcation and better osteoconductivity at the graft
site. Another important advantage of adding a graft material
isthesuperiorspacemaintenanceassociatedwithit.TheACS
is helpful as a carrier and gradually releases the BMP into the
defectovertheﬁrstweeksduringosteogenesis.Unfortunately
it is easily deformed and it is inadequate in maintaining the
space necessary to obtain an optimal bone regeneration.
In spite of these diﬀerences, the surgical technique desc-
ribed for the mandibular reconstruction is similar in all the
studies considered. Some diﬀerences can be found according
to the nature of the lesion.
The analysis of the two studies in which the failures were
reported reveals possibilities as to why they failed. In the
study by Carter et al., two patients out of ﬁve failed to form
adequate bone. In the ﬁrst patient, there was chronic infec-
tion with bacteria cultured from the bone at the time of
rhBMP-2 placement. Also the reconstruction plate fractured
at some point postoperatively and led to mobility of the segi-
ments. The second patient also had osteomyelits with active
infection requiring multiple incision and drainage proced-
ures. Both patients exhibited poor compliance and active in-
fection. One of the contraindications for the use of rhBMP-2
is the presence of active infection. In the study by Glied and
Kraut, a cadaveric rib was utilized to provide space main-
tenance for the rhBMP-2. It is possible that this technique
provided inadequate framework. It is also possible that the
cadaveric rib was insuﬃciently secured into place thereby
producing mobility in the area of the defect. Another pa-
tientintheirserieswasafracturepatientwithhistoryofoste-
omyelitis which may have contributed to the minimal bone
formation.
7. Conclusions
There is general agreement among these authors that osteo-
inductivematerialsmaybeusefulindecreasingsurgicalmor-
bidity and intraoperative time. Even if autogenous bone is
still considered the gold standard for reconstruction of man-
dibular defects, the possibility to obtain the same goal while
avoiding autogenous bone harvest is an important aspect to
take in consideration.
Based on the small number of studies present in the lit-
erature as well as the 13.5% failure rate reported, it is not
possible to conclude that growth factors can replace the need
f o ra u t o l o g o u sb o n eg r a f t sa tt h i st i m e .T h ea p p l i c a t i o no f
rhBMP with an absorbable sponge collagen appears to be a
very promising technique. However, more comparative stud-
ies and randomized controlled clinical trials will help to de-
termine the true eﬃcacy of this technique as well as optimal
carrier and scaﬀold.
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